[ET Net News Agency, 15 July 2020] CSPC Pharmaceutical Group Limited (01093) said
"Celecoxib Capsules (100mg, 200mg)" developed by CSPC Ouyi Pharmaceutical Co., Ltd., a
subsidiary of the company, has obtained drug registration approval granted by the National
Medical Products Administration of the People's Republic of China. It is the third generic
drug of this type passing the consistency of quality and efficacy evaluation in China.
Celecoxib is a nonsteroidal anti-inflammatory drug indicated for: (1) the management of
the symptoms and signs of osteoarthritis; (2) the management of the symptoms and signs of
rheumatoid arthritis in adults; (3) the management of acute pain in adults; and (4) the
management of the symptoms and signs of ankylosing spondylitis. (RC)